Major cable and broadcast news outlets seem to have largely ignored a Wall Street Journal report that Donald Trump Jr. stands to potentially benefit financially from a deal between BlinkRx and the government-run TrumpRx pharmaceutical program. Apparently, neither The New York Times or The Washington Post covered the Journal’s findings either.
Two words explain why: Brendan Carr.
Any broadcast that upsets Trump’s grift, is going to get a lot of heat from FCC Chairman and Trump stooge, Brendan Carr.